Monitoring Bladder Cancer

Patients with a history of urothelial carcinoma (UC) need regular monitoring for recurrence, even years after successful treatment. Consistent bladder cancer surveillance helps clinicians catch recurrent cancer early and gives patients peace of mind.

Unfortunately, many methods of monitoring bladder cancer involve uncomfortable, invasive procedures such as cystoscopy. These can take a significant toll on a patient's quality of life.

Cxbladder Monitor is a non-invasive urine-based laboratory test designed to help rule out the recurrence of bladder cancer. It offers a new approach and potential alternative to the current invasive surveillance protocol for many patients.

A Better Way to Monitor Bladder Cancer

Cxbladder Monitor is a painless, non-invasive urine test that helps rule out recurrent UC by measuring five messenger RNA (mRNA) biomarkers present in higher quantities in the urine of patients positive for the disease.

With a single urine sample, your patient can receive the confidence of a negative surveillance test without the discomfort or stress of an invasive procedure. We can deliver results quickly, within seven business days of receiving your patient's sample. Only a small sample of urine is needed and refrigeration is not required, making Cxbladder Monitor ideal for convenient, long-term UC surveillance.

Accurate Testing

Cxbladder Monitor accurately helps rule out recurrent bladder cancer, delivering a combined segregation score calculated from five genotypic biomarkers in the urine, and from clinical information about previous UC.

By testing for cancer signatures at the molecular level, Cxbladder can produce accurate results even at early stages.

We calculate our test results objectively, using a mathematical formula to accurately report the probability of bladder cancer with little room for human error.

Reliable Results

Cxbladder Monitor delivers reliable test results to you and your patients. With high negative predictive value (97.0%) and sensitivity (93.0%), Cxbladder Monitor helps you to confidently rule out patients with a low risk of recurrent disease and identify those at higher risk of recurrence who may need further clinical workup.

In clinical tests, Cxbladder Monitor significantly outperformed other urine-based tests, including cytology, making it ideal for patients who need reliable monitoring for UC.

Who Should Use Cxbladder Monitor?

Cxbladder Monitor is designed specifically to monitor patients with a history of bladder cancer. Clinicians can recommend these tests as a replacement for routine cystoscopy or complement to other surveillance methods.

Cxbladder may particularly help patients who want a more convenient method of monitoring their health or those who have personal, physical or religious reasons for avoiding invasive procedures.

Clinical applications for Cxbladder Monitor include:

  • Replacing other urine-based tests used in surveillance for recurrent UC
  • Surveillance for recurrent UC as the preferred adjunct to cystoscopy
  • Use as a confirmatory negative adjunct to cystoscopy, reducing the need for additional investigational tests and procedures
  • Continued surveillance for recurrent UC patients
  • Monitoring patients who may not tolerate cystoscopy for medical or religious reasons
  • Improving patient compliance with accurate and non-invasive testing

For ruling out and detecting UC in patients without a history of the disease, Cxbladder Triage and Cxbladder Detect provide more tailored options.

Choose Cxbladder Monitor for Bladder Cancer Surveillance

Patients with a history of urothelial carcinoma need cancer monitoring tests they can trust to deliver accurate and fast results without disrupting their quality of life. As these patients have a higher risk of developing recurrent bladder cancer, a reliable surveillance test can make a world of difference in early detection and treatment.

When combined with your professional interpretation and guidance, Cxbladder Monitor can help your patients live long and healthy lives after initial treatment. The test's sensitivity and high negative predictive value mean your patient gets peace of mind with every test result.

To learn more about the benefits and applications of Cxbladder Monitor, contact us today.

  • References

    Kavalieris L, O’Sullivan PJ, Frampton C, et al. Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study. J Urol 2017;197:6,1419-1426. [pdf available]


    Lotan Y, Hershey JR, Shariat S, et al. The development and clinical validation of a high sensitivity urine biomarker test for the determination of recurrence in urothelial carcinoma patients. American Urological Association Annual Meeting 2016; San Diego, CA, USA. Read abstract


    Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of noninvasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;:1–8. [pdf available]